Markets

Spero Therapeutics files for a $86 million IPO

Spero Therapeutics, which is developing treatments for MDR bacterial infections, filed on Friday with the SEC to raise up to $86 million in an initial public offering.

The Cambridge, MA-based company was founded in 2013 and booked $1 million in revenue for the 12 months ended June 30, 2017. It plans to list on the Nasdaq under the symbol SPRO. Spero Therapeutics filed confidentially on August 25, 2017. BofA Merrill Lynch, Cowen & Company, Stifel and Oppenheimer & Co. are the joint bookrunners on the deal. No pricing terms were disclosed.

The article Spero Therapeutics files for a $86 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More